The immune system has the utmost prospective for the targeted annihilation of tumors in combating metastasis. Imagine if we attack the tumors and malignant tissues while there is no additional toxicity to the rest of the body and especially the healthy tissues. Noted: There will be a delayed memory; latent efficacy of a sort, with can prevent the cancer to come back. The Research and Development of immune - oncology has been excelling in the past 30- 40 years. But some believe that the notion of using one's body to fight the ill is as old as medicine to the mankind. There are concrete evidence that this combative notion to fight cancer works and viably needed to be explored further. It is recognized that the development and there lack of control of the neoplastic tissues are not well appreciated and understood. Yet, we have learned the body can fight the disease including cancer using its self-destructive mechanisms against cancer via antibodies/antigen process. Immuno- surveillance targets have shown that the right combination if immune therapeutic agents will fight the antigenic phenomenon of neoplastic tissues and its mutagenic behavior. Global Allied Pharmaceuticals; www.gapsos.com, has recognized the role of immune- oncology and its combination therapy elements. We believe in the nature of Immunotherapeutic agents all the while their developing of specifies are a subject of further evaluation. The nature of the trials requires clinical and scientific expertise in immune oncology and cancer research. GAP has the necessary credentials.

Among many different and a variety of malignancies, the disease progression is collaborated with immune suppressive elements collectively working with the responsive anti- neoplastic nature of an antibody to destroy the malignancy. In exchange the tumors make a poor target to be attacked if the attaching cells including the so called natural killer of T- cells are not there to protect the diseased tissues. Noted: That is the primary concept of increasing the T- cells in many cases. In the absence of sensitivity to complement the natural work of the so called killer cells to work in stopping the progression of cancer. The leaky surrounding tissues of a solid tumor are highly antigen- prone and specific to the type of antigen that needs to work against the antibody. The most described notion associated with the T- cells are their regulatory nature as well as suppressions of the cells proliferative behavior. The primary pillar of the body's regulations, halting the disease to engulf the body into its demise of malignancy and ceasing the challenges of lack of survival. The body will learn to fight the invaders and its enemies from within. The robust profile of immune- oncology treatments in the last decade has brought us to better appreciate the self- regulating elements of our bodies.

Research associated with immune oncology and the natural interactions of the immune system of our bodies have shown that all adaptive immune mechanism may interfere in the disease progression and/or metastasis of the underlying tumor per se. As soon as few neoplastic cells are recognized by the so called natural killer cells the effectors mechanism of the immune system will kick into action. There are cells that are destructed due to the lack of recognition by the initial killer cells known as "transformers/transfer cells." T and B cells are both known to play a role in the fight against malignancy and activation of the mutagenic cells. Our immune system adapts to the nature of the assaulting malignant cells, but, its lack of transformation will keep the immune system as the primary soldier to fight cancer.